GC Biopharma’s ALYGLO grows fourfold as Q2-Q3 peak sales season nears

GC Biopharma is drawing expectations for improved performance on the back of growth in ALYGLO, its immunoglobulin plasma-derived product. According to market analysis, ALYGLO’s U.S. sales were assessed to have expanded to about four times the year-earlier level. Sales of plasma-derived products and vaccines usually tend to be concentrated in the second and third quarters, making that period a peak season for the company’s earnings. For ALYGLO, expanded sales channels and higher brand awareness are cited as key factors in settling into the U.S. market. At the same time, marketing costs, plant expansion and investment in plasma centers remain necessary. Whether sales are concentrated in Q2 and Q3 is expected to be a key indicator for the company’s earnings trend. Source: hankyung.com.